Nucletron and Advanced Radiation Therapy (ART) Jointly Announce a Global, Strategic Partnership to Offer AccuBoost(R) for Image-Guided Breast Irradiation



    
    -   Pay-Per-Patient Pricing Available to Reduce Start-Up Barriers for
        Cancer Centers
    

    COLUMBIA, MD and BILLERICA, MA, Feb. 12 /CNW/ - Nucletron, a
knowledge-based leader in radiation oncology, and Advanced Radiation Therapy
(ART) announced today an exclusive global, strategic partnership to offer the
AccuBoost(R) system with the microSelectron(R) high- dose rate (HDR)
brachytherapy afterloader treatment delivery solution for the treatment of
breast cancer. The partnership will enable clinicians all over the world to
deliver boost brachytherapy as part of the whole breast irradiation procedure,
providing a superior treatment option with the ultimate goal of improving
clinical outcome.
    The partnership offers radiation oncology centers the opportunity to
implement ART's innovative technology in image-guided HDR breast brachytherapy
on a pay-per-patient pricing model, along with a full complement of
Nucletron's treatment planning, treatment delivery, training, licensing,
reimbursement, and customized service support. ART's expansion of AccuBoost
technology through its global partnership with Nucletron will further reduce
the barriers to adoption of brachytherapy for cancer centers previously
deterred by the initial start-up costs usually associated with implementing a
breast brachytherapy program.
    "We are thrilled to partner with ART and expand the availability and
utilization of HDR brachytherapy globally," said Jos Lamers, chief executive
officer for Nucletron. "Using Nucletron's microSelectron Digital afterloader
to deliver AccuBoost technology further reduces the financial, operational,
and clinical barriers many cancer centers encounter in providing brachytherapy
to their patients. In conjunction with this announcement, Nucletron is
offering a pay-per-patient pricing model for centers bundling the AccuBoost
treatment option with their new HDR brachytherapy program, allowing these
centers to pay for the service when the boost treatment is delivered,
providing a more attractive financing model while delivering more treatment
options to their patients."
    "Advanced Radiation Therapy is pleased to partner with Nucletron," stated
Piran Sioshansi, Ph.D., president and chief executive officer of ART. "Our
goal is to make the AccuBoost treatment option available to as many women as
possible, all over the world. The market reach and expertise in HDR
brachytherapy provided by Nucletron will help us realize this goal. Together
we can accelerate the introduction of this new, non-invasive, image-guided
procedure to more clinical sites worldwide."
    Clinical reports indicate that patients with early stage breast cancer
have the best outcomes when the breast conserving lumpectomy procedure is
combined with a full course of whole breast irradiation and partial breast
boost dose. ART's AccuBoost combines a mammography procedure for real-time
image guidance to accurately target the boost dose, and precise dose delivery
by Nucletron's microSelectron family of HDR afterloaders. By increasing the
accuracy of the dose-targeting and reducing the unintentional exposure to
healthy tissue, including the heart, lungs, and skin, AccuBoost is expected to
improve patient outcomes, minimizes side effects and result in a better
cosmetic results.
    Representatives will be on hand to discuss this strategic partnership at
the American Brachytherapy Society's School of Breast Brachytherapy and
Brachytherapy Physics in San Antonio, TX on February 12-13, and the 2009 ACRO
Annual Meeting in Las Vegas, NV on February 26-27.

    About Nucletron

    Nucletron is a knowledge-based leader in Radiation Oncology, working with
clinical teams to realize innovative solutions that improve patient care.
Nucletron strives to offer the best possible choice of radiation modalities
through integrated products, software and services. Critical to the Nucletron
philosophy is the establishment of close working relationships with individual
clinical teams - reconfiguring traditional boundaries between customer and
solution provider. Many Nucletron employees have clinical experience
delivering oncology care, providing an in-depth understanding of the complex
needs of clinicians. For more information, visit http://www.nucletron.com.

    About Advanced Radiation Therapy (ART)

    ART is a women's health company dedicated to the advancement of partial
breast irradiation with the goal of reducing the cancer recurrence rate and
minimizing radiation related complications. ART's AccuBoost system combines
real-time, image-guidance with non-invasive, high-dose rate brachytherapy to
deliver a focused dose to the lumpectomy site. The AccuBoost technology is
based on the premise that the best method to immobilize, image and target
breast tissue is via mammography. As such, AccuBoost gives the clinicians the
comfort and confidence to "see what you treat and treat what you see" and
significantly reduces the unintentional exposure to the patient's heart and
lungs. For more information, visit http://www.AccuBoost.com.





For further information:

For further information: Nucletron B.V., PO Box 930, 3900 AX Veenendaal,
The Netherlands, Phone +31(0)318-557133; Media Contact: Danielle Davis, (443)
834-6725, ddavis@rosecomm.com

Organization Profile

NUCLETRON BV

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890